By Reuters
Medtronic Inc. has won U.S. approval for a new generation of implantable defibrillators designed to cut back on inappropriate shocks delivered by the devices, the company said on Monday.
A defibrillator is designed to shock a dangerously irregular heartbeat back to its normal rhythm. Get the full story »
By Dow Jones Newswires-Wall Street Journal
Medical-sector companies are passing out thousands of iPad tablet computers to salespeople to spruce up their pitch to doctors, and at the same time giving Apple Inc. a crucial foot in the door to business customers.
Abbott Laboratories, Medtronic Inc. and Boston Scientific Corp. are among the drug and medical-device firms making the move, while others say they are testing out the devices. Get the full story »
Oct. 29, 2010 at 5:22 p.m.
Filed under:
Government,
Health care,
Recalls
By Reuters
U.S. health regulators say a recalled Medtronic Inc. tissue device could cause more problems than originally thought, the company said Friday.
The device maker recalled its Octopus Nuvo Tissue Stabilizer in September because part of it could break, leading to fragments falling into patient chests and damaging the heart. Get the full story »
Aug. 24, 2010 at 1:02 p.m.
Filed under:
Earnings,
Health care,
Manufacturing
By Reuters
Medtronic Inc. posted a surprising decline in quarterly sales and cut its forecast due to weak demand for its medical devices and pressure on prices, sending its shares down nearly 12 percent to a 15-month low.
The world’s No. 1 stand-alone medical device maker, a bellwether, reported quarterly profit in line with expectations, but weak sales and outlook weighed on the shares of rivals such as cardiovascular device companies Boston Scientific Corp. and St. Jude Medical and orthopedic device makers Stryker Corp. and Zimmer Holdings. Get the full story »
July 28, 2010 at 2:06 p.m.
Filed under:
Pharmaceuticals
By Reuters
Researchers have developed an implantable sensor that measures blood sugar continuously and transmits the information without wires — a milestone, they said, in diabetes treatment.
The device worked in one pig for more than a year and in another for nearly 10 months with no trouble, said a report in the journal Science Translational Medicine. Get the full story »